




Life Sciences

2012: Life sciences leaders turn to WilmerHale for legal advice and business advantage. We provide incisive solutions to the business challenges facing biotechnology, pharmaceutical and medical device companies at all stages of growth. For more than four decades, we have represented life sciences clients in venture financings, public offerings, mergers and acquisitions, and licensing agreements and collaborations; protected their innovations through patent prosecution and portfolio development; defended their interests in enterprise-critical patent litigation; and navigated regulatory issues vital to their success.

Counsel of Choice to Life Sciences Innovators

SERVING INDUSTRY LEADERS IN BIOTECHNOLOGY, PHARMACEUTICALS, MEDICAL DEVICES AND BEYOND



Mergers and Acquisitions

 Acquisition of Phadia €2,470,000,000 August 2011	 Acquisition of Caliper Life Sciences \$600,000,000 November 2011	 Acquisition by Amgen \$1,000,000,000 (including milestone payments) March 2011	 Acquisition by Pfizer \$56,000,000 October 2011	
 Acquisition by Baxter International \$338,000,000 (including milestone payments) May 2011	 Acquisition by Alexion Pharmaceuticals \$1,080,000,000 (including milestone payments) February 2012	 Acquisition by Biogen Idec \$562,500,000 (including milestone payments) March 2012	 Acquisition of HealthDataInsights \$400,000,000 December 2011	 Acquisition by Alexion Pharmaceuticals \$111,000,000 (plus milestone payments) January 2011

Public Offerings

 Public Offering of 5.00% Senior Notes \$500,000,000 Counsel to Issuer October 2011	 Public Offerings of Senior Notes \$4,300,000,000 Counsel to Issuer February and August 2011	 Initial Public Offering of Common Stock \$63,250,000 Counsel to Issuer January 2012	 Public Offering of Common Stock \$60,900,000 Counsel to Issuer June 2011	 Initial Public Offering of Common Stock \$105,297,000 Counsel to Issuer March 2012	
 Initial Public Offering of Common Stock \$42,000,000 Counsel to Issuer February 2011	 Public Offerings of Common Stock \$124,958,000 Counsel to Issuer April and November 2011	 Public Offering of Common Stock \$111,162,000 Counsel to Issuer June 2011	 Public Offering of 4.75% Convertible Senior Notes \$230,000,000 Counsel to Issuer February 2011	 Public Offering of Common Stock \$86,250,000 Counsel to Underwriters May 2011	 Public Offering of Common Stock \$175,822,000 Counsel to Underwriters January 2011

Strategic Alliances and Collaborations

 Flu vaccine alliance with GlaxoSmithKline	 Global alliance with Astellas Pharma for tivozanib oncology product	 Sale of Victrelis royalty interest to CPPIB Credit Investments	 Collaborations with Celgene, Eisai and GlaxoSmithKline	 Drug development and commercialization agreements	 Oncology collaboration with Servier Laboratories
 Alliance with PharmaEngine for nanoliposomal irinotecan	 Alliances with AstraZeneca and with Roche and Spinal Muscular Atrophy Foundation	 Oncology channel partnership agreement with Intrexon and Asian collaboration with Solasia	 License to Avanir of deuterated dextromethorphan products	 Collaboration and option agreements with Genentech	

Venture Capital Financings

 \$15,000,000 First Round September 2011	 \$77,000,000 Late Stage April 2011	 \$47,600,000 First Round December 2011	 \$78,000,000 Third Round November 2011	 \$15,000,000 Second Round September 2011	
 \$6,000,000 First Round July 2011	 \$15,000,000 Fourth Round December 2011	 \$23,000,000 Fourth Round September 2011	 \$10,000,000 Second Round December 2011		



Mixed Sources
Product group from well-managed
forests, controlled sources and
recycled wood or fiber
www.fsc.org Cert no. BV-COC-070904
© 1996 Forest Stewardship Council

12_147 UNI 5/12 4,000

WilmerHale recognizes its corporate responsibility to environmental stewardship.

wilmerhale.com

Wilmer Cutler Pickering Hale and Dorr LLP is a Delaware limited liability partnership. WilmerHale principal law offices: 60 State Street, Boston, Massachusetts 02109, +1 617 526 6000; 1875 Pennsylvania Avenue, NW, Washington, DC 20006, +1 202 663 6000. Our United Kingdom offices are operated under a separate Delaware limited liability partnership of solicitors and registered foreign lawyers authorized and regulated by the Solicitors Regulation Authority (SRA No. 287488). Our professional rules can be found at www.sra.org.uk/solicitors/code-of-conduct.page. A list of partners and their professional qualifications is available for inspection at our UK offices. In Beijing, we are registered to operate as a Foreign Law Firm Representative Office. This material is for general informational purposes only and does not represent our advice as to any particular set of facts; nor does it represent any undertaking to keep recipients advised of all legal developments. Prior results do not guarantee a similar outcome. © 2012 Wilmer Cutler Pickering Hale and Dorr LLP